Article info
PDFEditors’ commentary
Highlights from this issue
Citation
Highlights from this issue
Publication history
- Accepted February 16, 2022
- First published March 17, 2022.
Online issue publication
March 19, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Systematic evaluation of nine monogenic autoinflammatory diseases reveals common and disease-specific correlations with allergy-associated features
- Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
- Familial Mediterranean fever (FMF) and beyond: a new horizon. Fourth International Congress on the Systemic Autoinflammatory Diseases held in Bethesda, USA, 6–10 November 2005
- Autoinflammatory syndromes in neurology: when our first line of defence misbehaves
- Autoinflammatory diseases: update on classification diagnosis and management
- Classification criteria for autoinflammatory recurrent fevers
- Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry
- Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers
- Visual loss with chronic meningeal and systemic inflammation
- An International registry on Autoinflammatory diseases: the Eurofever experience